CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications (Q38042321)

27 August 2017

title

CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications (English)

1 reference

27 August 2017

1 reference

Tom Seijkens

1

1 reference

27 August 2017

Pascal Kusters

series ordinal

2

1 reference

27 August 2017

David Engel

series ordinal

3

1 reference

27 August 2017

Esther Lutgens

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

10 September 2012

1 reference

Diabetes and Vascular Disease Research

27 August 2017

published in

1 reference

27 August 2017

volume

10

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

115-122

1 reference

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Glucose control and cardiovascular disease: is it important? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

The global burden of diabetes and its complications: an emerging pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

CD40 activation in human pancreatic islets and ductal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Requirement for CD154 in the progression of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

CD40 and autoimmunity: the dark side of a great activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Endoplasmic Reticulum Stress and Inflammation in Obesity and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Inflammatory links between obesity and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Five stages of evolving beta-cell dysfunction during progression to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Acute suppression of circulating sCD40L during hyperglycemia and euglycemic-hyperinsulinemia in healthy young males

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

The immune system in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Intensive glycemic control and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Glycemic control and complications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Biomarkers in fasting serum to estimate glucose tolerance, insulin sensitivity, and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

Soluble CD40 Ligand in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112455817

21 January 2018

Identifiers

DOI

10.1177/1479164112455817

1 reference

27 August 2017

1 reference